BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37280330)

  • 1. Computational modeling of DLBCL predicts response to BH3-mimetics.
    Cloete I; Smith VM; Jackson RA; Pepper A; Pepper C; Vogler M; Dyer MJS; Mitchell S
    NPJ Syst Biol Appl; 2023 Jun; 9(1):23. PubMed ID: 37280330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma.
    Smith VM; Dietz A; Henz K; Bruecher D; Jackson R; Kowald L; van Wijk SJL; Jayne S; Macip S; Fulda S; Dyer MJS; Vogler M
    Haematologica; 2020 Aug; 105(8):2150-2163. PubMed ID: 31601689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
    Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
    Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel form of caspase-independent cell death triggered by BH3-mimetics in diffuse large B-cell lymphoma cell lines.
    Yildirim N; Sarojam L; Smith VM; Pieper NM; Anders M; Jackson RA; Fuhrmann DC; Särchen V; Brücher D; Weigert A; Dyer MJS; Vogler M
    Cell Death Dis; 2024 Apr; 15(4):266. PubMed ID: 38622118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of lymphoma-linked Asn11Tyr point mutation on the interaction between Bcl-2 and a BH3 mimetic: Insights from molecular dynamics simulation.
    Singh K; Briggs JM
    Chem Biol Drug Des; 2020 Apr; 95(4):435-450. PubMed ID: 32030875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins.
    Renault TT; Elkholi R; Bharti A; Chipuk JE
    J Biol Chem; 2014 Sep; 289(38):26481-26491. PubMed ID: 25096574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
    Akl H; Vervloessem T; Kiviluoto S; Bittremieux M; Parys JB; De Smedt H; Bultynck G
    Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
    Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
    Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
    Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
    Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.
    Thompson RC; Vardinogiannis I; Gilmore TD
    PLoS One; 2013; 8(5):e62822. PubMed ID: 23667527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma.
    Roh J; Pak HK; Jeong S; Hwang S; Kim DE; Choi HS; Kim SJ; Kim H; Cho H; Park JS; Jeong SH; Choi YS; Han JH; Yoon DH; Park CS
    Biochem Biophys Res Commun; 2023 Sep; 673():36-43. PubMed ID: 37356143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The carboxyl-terminal sequence of PUMA binds to both anti-apoptotic proteins and membranes.
    Pemberton JM; Nguyen D; Osterlund EJ; Schormann W; Pogmore JP; Hirmiz N; Leber B; Andrews DW
    Elife; 2023 Apr; 12():. PubMed ID: 37078707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
    Scarfò L; Ghia P
    Immunol Lett; 2013; 155(1-2):36-9. PubMed ID: 24095849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B-cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis.
    Dietz A; Dalda N; Zielke S; Dittmann J; van Wijk SJL; Vogler M; Fulda S
    Int J Cancer; 2020 Sep; 147(5):1485-1498. PubMed ID: 32170726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
    Bojarczuk K; Wienand K; Ryan JA; Chen L; Villalobos-Ortiz M; Mandato E; Stachura J; Letai A; Lawton LN; Chapuy B; Shipp MA
    Blood; 2019 Jan; 133(1):70-80. PubMed ID: 30322870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
    Turner BC; Eves T; Refaeli Y
    DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of the interactome of Bcl-2 proteins in breast cancer at the transcriptional, mutational and structural level.
    Kønig SM; Rissler V; Terkelsen T; Lambrughi M; Papaleo E
    PLoS Comput Biol; 2019 Dec; 15(12):e1007485. PubMed ID: 31825969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
    Dey J; Deckwerth TL; Kerwin WS; Casalini JR; Merrell AJ; Grenley MO; Burns C; Ditzler SH; Dixon CP; Beirne E; Gillespie KC; Kleinman EF; Klinghoffer RA
    Sci Rep; 2017 Dec; 7(1):18007. PubMed ID: 29269870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL-W is dispensable for the sustained survival of select Burkitt lymphoma and diffuse large B-cell lymphoma cell lines.
    Diepstraten ST; Chang C; Tai L; Gong JN; Lan P; Dowell AC; Taylor GS; Strasser A; Kelly GL
    Blood Adv; 2020 Jan; 4(2):356-366. PubMed ID: 31985804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.